The world marathon towards the Corona vaccine ... a Chinese company tests it on employees without a permit, and the Russians need to vaccinate 50 million

As the world witnesses a race to develop a vaccine against the emerging coronavirus, SARS Cove 2, which causes Covid-19, it is clear that a Chinese company has tested a vaccine against employees without obtaining approval to test it in humans. For their part, researchers from America, Europe and Russia continue their experiences.

We start in China, where a subsidiary of the SINOPHARM Foundation reported that "30 special volunteers rolled up their arms and helped" to test the vaccine, before approval was given to test it on humans, according to Anatolia news agency.

The company attached to the post a photo of scientists and businessmen, mediated by a Communist Party official, stressing the "spirit of sacrifice." She explained that the initial test, conducted at the end of March, aims to ensure that vaccines are released as soon as possible.

"Sino Farm", which did not comment on the publication, confirmed that it is working on two hypothetical vaccines against the Corona virus, and indicated that the government agreed to it last April to carry out the first stage experiments, that is, to test it in humans.

It is worth noting that the "Sino Pharm" test for human vaccine without a permit is "a violation of international ethical rules."

Multiple experiences

The French newspaper Les Echos said that our American Moderna laboratory will be the first to launch on July 27 the experience of the third stage of the race to the vaccine against the emerging coronavirus that causes Covid-19, noting that Pfizer and Astra Zenica (AstraZeneca) and Novavax are pushing ahead.

Our modern laboratory announced that the experiment will include thirty thousand people, half of whom will receive the vaccine and the other half will receive placebo, and the volunteers will receive two consecutive doses and will be followed for a period of two years, so the test results are not expected until October 2022.

But this does not mean that the vaccine will not be available before that, as it can - according to the newspaper - be provided to patients in late 2020 or early 2021, if he obtained emergency permission. Analysts estimate that 50 million people can be vaccinated in 2021, at an estimated cost of about $ 50 per dose, allowing Moderna, which intends to produce one billion doses annually, to sell $ 5 billion in 2021.

Antibodies

In conjunction with the announcement of the launch of the third stage, our moderator published detailed results of her experience in the first phase, which includes 45 people, in the New England Journal of Medicine.

The magazine pointed out that all participants in the experiment produced antibodies that eliminate the virus in large proportions similar to those produced by the recovered after infection with the Coruna virus, but this good news is accompanied by side effects such as fever, headache and muscle pain, more than traditional vaccines.

As for Pfizer Laboratories, it is planning to start the third stage before the end of July, and it relies for its vaccine on the same RNA technology as our director.

In August, AstraZeneca and its partner from the University of Oxford are expected to launch the third phase, followed by "J & J" in September and then US Novafax Biotechnology in the fall.

On the Chinese side, the CanSinBio vaccine has been listed for the second phase since June, and it has been combined with products available to treat the Chinese army for one year, though it is not clear whether it is preventive or curative.

With many vaccines likely to obtain an emergency permit, Pfizer promised to manufacture 100 million doses in 2020, and AstraZinka promised to manufacture 300 million, and Novafax to manufacture 100 million, and our manager, who also committed to several million doses, signed several agreements in this regard.

Russia

The head of the sovereign wealth fund Kirill Dimitriev told Reuters that his country plans to produce 30 million doses of a pilot vaccine for Covid-19 disease this year, and it is also working to manufacture another 170 million doses abroad.

This week the first human experiment with the vaccine ended, which lasted for a month and included 38 people. The researchers concluded that the vaccine was safe to use, and led to an immune response, although the strength of this response is not yet clear.

Dmitriyev said the third-largest trial, which includes several thousand, is expected to start in August. "We believe that based on the current results it will be approved in August, and in some other countries in September ... which makes it probably the first vaccine to be approved in the world," he added.

He also told Reuters: "There is a general feeling that the so-called herd immunity in Russia needs to be vaccinated between 40 and 50 million."

"So we think we will be in a good position to produce about 30 million (doses locally) this year, and after that we can finish the vaccination process next year."

He explained that Russia has entered into manufacturing agreements with five other countries, and could produce up to 170 million doses abroad this year.

The Swiss drug company Novartis said its Sandoz unit would reap profits from the distribution of 15 properties whose patent period has expired, and is available for production in the same original formulation in developing countries to treat Covid-19 symptoms.

Shanghai Fosun Pharmaceutical, the local partner of German Biontech, has announced that China has agreed to an early-stage human trial of a Covid-19 trial drug conducted by Biontech.